Intellia Therapeutics to Present at Morgan Stanley Healthcare Conference

CAMBRIDGE, Mass., Sept. 04, 2026 /CourierPR/ -- Intellia Therapeutics, a biopharmaceutical company at the forefront of gene editing technology, will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, at 4:05 p.m. ET.

The presentation, which will be live-streamed, will be accessible on the Events and Presentations page of Intellia’s website, www.intelliatx.com. A replay will remain available for approximately 90 days.

Founded in 2013, Intellia Therapeutics is dedicated to developing potentially curative treatments for severe diseases using CRISPR gene editing and other core technologies. The company aims to transform medicine by addressing the root causes of diseases in a durable manner.

Intellia's mission is to improve the lives of patients suffering from severe diseases by leveraging its innovative technologies. The company has already demonstrated significant progress, with clinical trials showing promising results in treating a range of diseases, including those related to rare genetic disorders and certain cancers.

"The Morgan Stanley conference is a key event for our team to engage with investors and healthcare professionals, fostering dialogue and advancing our mission to revolutionize medicine," added Fredette.

Intellia's approach to CRISPR gene editing is designed to provide long-term solutions by directly targeting the genetic mutations responsible for disease. The company's pipeline includes multiple programs aimed at treating various conditions, with a particular focus on rare genetic diseases and cancers.

As the company continues to advance its technologies and clinical trials, the upcoming presentation at the Morgan Stanley conference is anticipated to highlight significant milestones and future prospects.